Voyager Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Voyager Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $65.30 million for the year ending 2025.

  • Voyager Therapeutics, Inc. showed a decrease of -8.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q3 2014: $6.33 million | Q1 2015: $116.41 million | Q2 2015: $84.75 million | Q3 2015: $66.53 million | Q1 2016: $33.90 million | Q2 2016: $67.03 million | Q3 2016: $63.51 million | Q1 2017: $43.60 million | Q2 2017: $66.30 million | Q3 2017: $48.20 million | Q1 2018: $140.37 million | Q2 2018: $59.61 million | Q3 2018: $42.14 million | Q1 2019: $113.26 million | Q2 2019: $79.89 million | Q3 2019: $82.64 million | Q1 2020: $165.23 million | Q2 2020: $144.32 million | Q3 2020: $147.45 million | Q1 2021: $117.80 million | Q2 2021: $117.84 million | Q3 2021: $111.48 million | Q1 2022: $131.87 million | Q2 2022: $78.33 million | Q3 2022: $96.86 million | Q1 2023: $268.32 million | Q2 2023: $244.29 million | Q3 2023: $65.27 million | Q1 2024: $143.08 million | Q2 2024: $76.13 million | Q3 2024: $112.53 million | Q1 2025: $74.76 million | Q2 2025: $43.94 million | Q3 2025: $45.13 million.
  • Over the full 13 years of available data (2013 to 2025), Voyager Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 48,270.4%.
  • Historical annual values: Fiscal year 2025: $65.30 million | Fiscal year 2024: $71.37 million | Fiscal year 2023: $68.80 million | Fiscal year 2022: $98.96 million | Fiscal year 2021: $117.43 million | Fiscal year 2020: $104.44 million | Fiscal year 2019: $86.04 million | Fiscal year 2018: $46.86 million | Fiscal year 2017: $31.53 million | Fiscal year 2016: $36.64 million | Fiscal year 2015: $31.31 million | Fiscal year 2014: $7.04 million | Fiscal year 2013: $135.0 thousand.
  • Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: